---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-010342"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:52:36.646632+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA issues CRL for Atara's EBVALLO BLA, reversing prior stance on trial adequacy

## Summary
- FDA CRL received Jan 9, 2026; confirms GMP issues resolved but claims ALLELE trial inadequate for accelerated approval.
- Atara and partner Pierre Fabre plan to request Type A meeting within 45 days to seek path forward.
- Cash, cash equivalents and short-term investments as of Dec 31, 2025: approximately $8.5M.
- Atara implemented ~90% headcount reduction and reduced ARC lease liability by ~65% in 2025.
- Amendment to PFM agreement: approval milestone reduced to $31M, with potential $15M commercial milestone.

## SEC filing metadata
- accession: 0001193125-26-010342
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000119312526010342/0001193125-26-010342-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000119312526010342/d34257d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-010342
- JSON: https://secwatch.observer/filing/0001193125-26-010342.json
- Plain text: https://secwatch.observer/filing/0001193125-26-010342.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.